Lesley.SeymourMD

200 posts

Lesley.SeymourMD

Lesley.SeymourMD

@LSeymourMD

Medical Oncologist, Professor of Oncology Queens University, Director Investigational New Drug Program, Canadian Clinical Trials Group.

Kingston, Ontario Katılım Kasım 2017
53 Takip Edilen154 Takipçiler
Lesley.SeymourMD retweetledi
IND Program CCTG
IND Program CCTG@INDProgramCCTG·
@CDNCancerTrials Wonderful to have Carol join us in early clinical trials research
English
0
2
4
144
Lesley.SeymourMD
Lesley.SeymourMD@LSeymourMD·
Congratulations Joe - it’s been an enormous privilege to have (and continue to) work with you - your contributions to cancer research nationally and globally cannot be overstated
CCTG@CDNCancerTrials

Dr. Joseph Pater #CCTG's founding director recognized for a lifetime of work in cancer research with his appointment as an Officer of the Order of Canada - his clinical research has improved the lives of Canadians with cancer. #OrderOfCanada #GGHonours  ctg.queensu.ca/cctg_news/foun…

English
1
4
14
1.5K
Lesley.SeymourMD retweetledi
CCTG
CCTG@CDNCancerTrials·
#ASCO23 is this weekend stop by and see @ALLIANCE_org NCCTG N0147 (#CCTG CRC2): Artificial intelligence–derived immune phenotypes for prediction of prognosis in patients with stage III colon cancer Poster Session 3542: meetings.asco.org/abstracts-pres…
CCTG tweet media
English
0
2
4
398
Lesley.SeymourMD retweetledi
Annie Ellis
Annie Ellis@Stigetta·
Marie Plante: Int’l P3 trial radical hysterectomy & pelvic node dissection (RH) vs simple hysterectomy & pelvic node dissection (SH) in pts w/low-risk early-stage cervical ca (LRESC):  Gyn Cancer Intergroup study led by Canadian Cancer Trials Grp (CCTG CX.5-SHAPE) #ASCO23 #gyncsm
Annie Ellis tweet media
English
0
5
8
635
Lesley.SeymourMD retweetledi
GBOT Alerta
GBOT Alerta@GBOT_Alerta·
🧐IND.227: fase III randomizado comparando CIS/PEM X CIS/PEM/PEMBRO. N=440 ⬆️OS HR: 0,79. >>Impacto histologia ñ-epitelioide e > EORTC prognostic risk, contudo mediana numericamente inferior ao CK743. ↔️PFS ↔️TRO #ASCO23
GBOT Alerta tweet media
Português
0
4
11
334
Lesley.SeymourMD retweetledi
Marcelo Corassa, MD.
Marcelo Corassa, MD.@MarceloCorassa·
IND.227: PhIII, Platinum + Pem + Pembro x Platinum + Pem in mesothelioma. mOS 17.28 x 16.13 months, HR 0.79, p 0.0324. Pronounced benefit in patients with non-epithelial subtypes. #ASCO23 #LCSM @GBOT_Alerta
English
1
2
7
493
Lesley.SeymourMD retweetledi
Chul Kim
Chul Kim@chulkimMD·
IND.227: cisplatin/pemetrexed/pembrolizumab vs. chemo alone in pleural mesothelioma by Dr. Chu. OS (primary endpoint): 17.28 vs. 16.13 mo (HR 0.79, statistically sig). ORR: 61% vs. 38% (!), also favoring the combo Chemo-IO is a promising approach in mesothelioma
Chul Kim tweet mediaChul Kim tweet mediaChul Kim tweet media
English
1
4
6
1.7K
Lesley.SeymourMD retweetledi
Sanjay Popat
Sanjay Popat@DrSanjayPopat·
Great to see IND.227: long awaited. Chemo-pbro vs chemo. Mostly epithel subtyp. 61% CPS+ OS improved HR0.79, 16 to17mo median; PFS benefit. CPS not predictive. Great work @CDNCancerTrials Will the addition of beva improve this? Let’s see… #ASCO23 @etop_ibcsg
Sanjay Popat tweet mediaSanjay Popat tweet mediaSanjay Popat tweet mediaSanjay Popat tweet media
English
2
12
35
4.5K
Lesley.SeymourMD retweetledi
Jordi Remon
Jordi Remon@JordiRemon·
IO+Chemo work in all thoracic 🫁 malignancies including pleural mesothelioma: IND227 trial. Results mirror CheckMate 743. Today the dilemma in 1st L: IO+IO vs IO+CT? We need predictive mrk for choosing 1st L or decide based on histology subtype:IO+IO non-epithelioid? #ASCO2023
Jordi Remon tweet mediaJordi Remon tweet mediaJordi Remon tweet media
English
1
21
42
9.9K

Keşfet

@CDNCancerTrials @myESMO @curzua_28 @istitutotumori @IFCTlung @INDProgramCCTG @ALLIANCE_org @GBOT_Alerta